Research Article

CD4-Targeted T Cells Rapidly Induce Remissions in Mice with T Cell Lymphoma

Jie Cheng,1,2 Guanghua Chen,3 Hui Ly,1 Liangjing XU,3 Huiwen LIU,3 Tianping Chen,2 Lijun Qu,2 Jian Wang,2 Lemei Cheng,2 Shaoyan Hu,1 and Yi Wang1

1Department of Hematology, Children’s Hospital of Soochow University, Suzhou, Jiangsu Province, China
2Department of Hematology, Anhui Provincial Children’s Hospital, Anhui Province, China
3Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou Jiangsu Province, China

Correspondence should be addressed to Yi Wang; yiwang19992020@163.com

Received 31 December 2020; Revised 8 February 2021; Accepted 5 March 2021; Published 28 March 2021

1. Introduction

T cell lymphoma is a rare form of cancerous lymphoma affecting T cells and patients with cutaneous T cell lymphoma (CTCL) are at a higher risk of developing second malignancies [1]. There is no effective treatment for this debilitating disease so far. Anti-PD-1 and anti-CTLA-4 antibodies have been recently developed as checkpoint reagents in the treatment of various cancer patients including Hodgkin lymphoma and showing some promising results in clinical trials [2–4]. Other reagents, such as TIM-3, TIGIT, BTLA, CD47, and KIR that target the adaptive and innate immune system are recently developed as alternative ways to activate the immune system [5]. However, the results were elusive among patients with non-Hodgkin lymphomas.

T cell-mediated therapy against cancer was developed in 2003 by Dr. Rosenberg through amplification and adoptive transfer of tumor-infiltrating lymphocytes (TILs) in the patients; the therapeutics have been confirmed great success in patients with melanoma [6, 7]. Because the number of TILs from patients is limited and the expansion of TILs in vitro is difficult, a novel T cell therapy approach was developed recently, by which naive T cells were modified to express chimeric T cell antigen receptor (CAR) encoding tumor-associated antigen- (TAA-) specific single-chain antibody fragment (scFv) and intracellular domain of CD3zeta [8–10]. After the cognate CAR-T cells were administered into cancer patients, the adoptively transferred T cells can migrate into tumor sites by specifically binding to TAA on cancer cells. A body of evidence confirmed that CAR-T cells have longer survival ability and more cytotoxic effects in vivo with intracellular activation domains, 4-1BB and CD3zeta [11, 12]. Recently, CD19-targeted CAR-T cell therapy has been successfully explored in clinical trial and showed an
2. Materials and Methods

2.1. Construction of Lentiviral Vectors. A CD4-CAR fusion protein fragment containing a single-chain antibody fragment (scFv) specific for CD4 antigen, costimulatory factor CD28 fragment, and intracellular signal transduction domain of CD3 fragments was constructed into pGIPZ transfer vector (Cat. TLP4614, Open biosystems, Huntsville, AL, USA, Figure 1(a)). The correct insert and DNA sequence in the plasmid were confirmed by enzyme digestion. The control reporter plasmid pRL Renilla luciferase reporter pRL-CMV vector (Cat. E2261, Promega, Madison, WI, USA) was used as controls. The fusion protein expression was further determined by Western blot analysis after transfer into 293T cells. The transfer recombinant plasmid was then engineered into lentiviral vector Lv.CD4-CAR by cotransfection of 293T viral packaging cells with this plasmid and other packaging plasmids (pTLA1-Pak, pTLA1-Env, pTLA1-Rev). 2 days after plasmids cotransfection, the conditional media of the transfected cells containing lentiviral vector Lv.CD4-CAR were collected and virus titer was determined in 293T cells and virus stock was frozen in -80°C freezer.

2.2. Lentivirus Transduction of T Cells. After lentiviral titer was determined, CD4+ T cells purified from peripheral blood in 6-well plate were incubated with anti-CD3 and anti-CD28 antibodies (Cat. 16-0037-81, 16-0289-81, eBioscience, San Diego, CA) to activate the naive T cells to improve lentiviral vector transduction efficiency, according to the previous report [12]. 24 hours after cell activation, the activated T cells were infected with the lentiviral vector at multiplicity of infection (MOI = 10) for 48 hours to obtain the engineered T cells expressing CD4-CAR on cell surface (CD4CART). The viral vector transduction efficiency was measured by protein L binding activity (Cat. ab155706, Abcam, Cambridge, MA). Because protein L can bind to the kappa light chain of scFv in chimeric antigen receptor (CAR) [24], protein L becomes an ideal reagent in the detection of CAR expression in the CD4-CART-transduced T cells. A high protein L binding activity reflects a high expression level of CD4-CAR on CD4CART cells. Finally, the engineered T cells were maintained and expanded in RPMI1640 culture media for 7 days before cell adoptive transfer.

2.3. CD4CART Cytotoxicity Assay In Vitro. After 7 days of expansion, the cytotoxic activity of CD4CART cells or control T cells on tumor cells was confirmed by incubation with T lymphoma cell line, CD4+ T1301 cells (Cat. 01051619-CDNA, Merck, Kenilworth, NJ) at a ratio of 0 : 1, 0.5 : 1, 1 : 1, 2 : 1, 4 : 1, and 8 : 1. After 24 hours of coculture and staining with anti-CD3 and anti-CD4 antibodies (Cat. 357407, 300307, Biocell, San Diego, CA), the depletion of CD4+ targeted tumor cells were analyzed by flow cytometry analysis.

2.4. CD4CART Cytotoxicity Assay In Vivo. 8-12 years old of male immune-deficient NSG mice (The Jackson Laboratory, Bar Harbor, Maine) were subcutaneously (s.c.) injected with 4 × 10⁶ CD4+ T1301 tumor cells to establish a mouse model with T cell lymphoma. All animal experiments were approved by the Committee of Animal Care and performed in the animal facility of Nanjing University of Medical School in China. 1 week after tumor cell inoculation, 1 × 10⁶ CD4CART single-cell suspension in 0.7 ml volume was intravenously administered into the mouse model. Meanwhile, the mouse model received the same doses of naive T cells or PBS was administered as untreated control group. Tumor size and mouse survival were recorded every other day.

3. Results

3.1. Generation of CD4CART Cells. Recombinant transgene plasmid pCD4-CAR containing a single-chain antibody fragment (scFv) specific for CD4 antigen, costimulatory factor CD28 fragment, and intracellular signal transduction domain of CD3 fragments was constructed by molecular cloning as shown in diagram of Figure 1(a). The correct insert in the recombinant plasmid was confirmed by EcoRI and BamHI digestion. After agarose gel electrophoresis, we observed a 1.5 kb band, indicating the presence of insert gene fragment, whereas null plasmid without insert did not contain the insert (Figure 1(b)). Lentiviral vector Lv.CD4-CAR containing CD4-CAR was generated by cotransfection of transgene plasmid pCD4-CAR and other packaging plasmids into 293T packaging cells. The conditional media of transfected cells containing lentiviral vector Lv.CD4-CAR were collected. The viral titer was measured in HeLa cells with serial dilution of viral vector. The unconcentrated viral titers were at a range of 0.8 – 1.0 × 10⁵ transducing units/ml (TU/ml).
To modify T cells with CD4-CAR, the naive T cells were infected with Lv.CD4-CAR at multiplicity of infection (MOI) of 10 for 2 days. The engineered T cells were maintained and expanded in RPMI1640 culture media for 7 days. The CD4-CAR expression level on engineered CD4CART cells was determined by measuring protein L binding activity to kappa light chain of scFv on CD4-CART cells. We observed that the protein L binding activity to CD4CART cells was as high as 47.5%, whereas the protein L binding activity to control T cells was only 2% (Figure 1(c)), indicating the high expression level of CD4-CAR on the modified T cells. Additionally, we also observed that CD4+ T subset was almost completely depleted 3-4 days following Lv.CD4-CAR transduction. However, the control T cells had the normal proportion of CD4+ T cells (Figure 2). The data indicated that CD4CART cells exhibit potent anti-CD4 activity in vitro.

3.2. CD4CART Cells Exhibited Potent Cytotoxic Activity In Vitro. To investigate the role of CD4CART cells in antitumor cell activity, we coincubated the CD4CART cells (effector cells, E) with CD4+ T1301 tumor cells, a T-ALL cell lines (target cells, T) at different E:T ratio. 24 hours after coculture, we observed a more reduced population of CD4+ T1301 tumor cells at an E:T ratio of 4:1 than the ratio at 2:1. However, the control T cells did not exhibit cytotoxic activity against CD4+ T1301 tumor cells (Figures 3(a) and 3(b)).

3.3. CD4CART Cells Exhibited Potent Cytotoxic Activity in Mice with T Cell Lymphoma. To evaluate in vivo antitumor activity of CD4CART cells, we developed a xenogeneic mouse model. Mice with lymphoma tumor were established by subcutaneously (s.c.) injection with $4 \times 10^6$ CD4+ T1301 tumor cells at armpit of 6-8 weeks old NSG mice. 1 week after tumor cell inoculation, $1 \times 10^8$ CD4CART single cells were intravenously administered into the tumor site of mouse model. Mice treated with the control T cells or PBS were as the untreated controls. 15 days after the treatment, we observed the slower tumor growth in the mice who received CD4CART cells (Group: CD4CART cells) than the mice who received the same doses of naive control T cells (Group: T cells) or PBS (Group: PBS) (Figure 2(a)). Quantitative analysis showed that the tumor size in CD4CART group was significantly smaller than the mice in both naive control T cell group and PBS control group ($p < 0.001, n = 10$). The mice treated with control T cells and PBS had an average tumor size of 80 mm$^3$ on day 17 posttumor cell inoculation (Figure 2(b)). However, the tumor size glowed very slowly in the mice treated with CD4CART cells, and 2 mice had disappeared tumor 30 days after the treatment.

3.4. CD4CART Cells Increased Survival of Mice with Lymphoma Tumor. Our further analysis showed that CD4CART cells significantly improved the survival of mice with T cell lymphoma. We observed 3 mice died,
respectively, on day 15, 23, and 30 after CD4CART cell treatment, and other mice remained healthy and survived until the end of the experiments on day 50. The survival rate reached up to 50%. However, 6 mice died on day 13, 18, 20, 21, 24, and 25, respectively, after the treatment with control T cells. 6 mice died on day 12, 20, 21, 21, 23, and 24, respectively, after treatment with PBS. All mice received control T cells and PBS died at the end of the experiment. The survival rate was comparable between mice treated with control T cells and PBS ($p > 0.05$, $n = 10$). Therefore, CD4CART cell treatment significantly improved the survival rate of mice, compared to the treatment with control T cells and PBS ($p < 0.001$, $n = 10$) (Figure 2(c)).

4. Discussion

T cell lymphoma is a rare form of cancerous lymphoma affecting T cells, which represents less than 15% of all non-Hodgkin’s diseases. Various risk factors and virus infections such as Epstein Barr virus and human T cell leukemia virus-1 account for the progression of T cell lymphoma [25, 26]. Unfortunately, there is no effective therapeutics for the debilitating disease so far. Cell-based therapy, particularly CAR-T cell therapy, has been confirmed effective in some B cell lymphatic diseases, such as B cell leukemia. However, CAR-T cell therapy for T cell lymphoma is not well developed so far. In this study, we explored a novel therapeutic approach in the treatment of murine T cell lymphoma by CAR-T adoptive cell transfer, in which a single-chain antibody fragment (scFv) specific for tumor-associated antigen CD4 was engineered into naive CD4+ T cells. To improve the modified T cell antitumor activity, scFv fragment was fused with costimulatory factor CD28 fragment and intracellular signal transduction domain of CD3 fragments [12]. Our results in vitro demonstrated that CD4 scFv-engineered T cells had potent cytotoxic effects on CD4+ T1301 tumor cells, a T-ALL cell lines at a concentration-dependent manner. The tumor cell viability was significantly reduced starting at E:T ratio of 0.5:1. The effects were further confirmed in tumor animal model, in which mice treated with CD4CART cells had much slower tumor growth and higher survival rate than the mice who received control T cells and PBS. We observed 3 death and 2 mice without tumor growth in the CD4CART, which reached the total survival rate up to 50% at the end of the experiment. However, all mice received the treatment with control T cells and PBS died at the end of the experiment. The results provided solid evidence that CD4CART cells were potent in the treatment of mice with T cell lymphoma.

In addition, we did not observe the side effects of CD4CART cell infusion in vivo. We speculate that the low side effects may be caused by high expression of CD4 in T cell
lymphoma but low expression in hematopoietic stem cells and normal CD4+ T cells. The concepts were also supported by previous studies showing that administration of monoclonal antibody against CD4 did not elicit significant side effects in autoimmune diseases, such as psoriasis [21] and multiple sclerosis [22, 23]. There are no reports so far about significant depletion of normal CD4+ T cells and suppression of immune system after anti-CD4 antibody treatment in animal model. Given that the population of normal CD4+ T cells is reduced after anti-CD4 antibody treatment [27], new normal CD4+ T cells should be effectively produced and expanded in bone marrow, and the number is gradually increased after monoclonal antibody treatment. Therefore, CD4+ normal T cells were reversible in vivo. CD4-targeted therapy is safe and effective in the treatment of T cell lymphoma. The survival, dynamics, and side effects of CD4CART cells will be further evaluated in the future.

5. Conclusion

In this study, we generated CD4-targeted T cell therapy for T cell lymphoma. The study in vitro and in vivo confirmed that CD4CART cells were potent in defense against T cell lymphoma without significant side effects. The study provided a novel therapeutic approach in the treatment of T cell lymphoma.

Data Availability

Some or all data, models, or code generated or used during the study are available from the corresponding author by request.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This study was supported by the (1) Project entrusted by National Center for clinical medicine of hematological diseases (2020WSB05), (2) Suzhou science and technology
References

[1] A. Goyal, D. O’Leary, K. Goyal, K. Patel, D. Pearson, and M. Janakiram, “Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer: a systematic review and meta-analysis,” Journal of the American Academy of Dermatology, 2020.

[2] P. De Silva, M. Aiello, C. Gu-Trantien, E. Migliori, K. Willard-Gallo, and C. Solinas, “Targeting CTLA-4 in cancer: is it the ideal companion for PD-1 blockade immunotherapy combinations?,” International Journal of Cancer, 2020.

[3] A. Hallqvist, A. Rohlin, and S. Raghavan, “Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer,” Scandinavian Journal of Immunology, vol. 92, no. 6, article e12990, 2020.

[4] M. Perez-Santos, “Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors,” Pharmaceutical Patent Analyst, vol. 9, no. 5, pp. 149–154, 2020.

[5] M. Joshi and S. M. Ansell, “Activating the antitumor immune response in non-Hodgkin lymphoma using immune checkpoint inhibitors,” Journal of Immunology Research, vol. 2020, Article ID 8820377, 12 pages, 2020.

[6] M. E. Dudley and S. A. Rosenberg, “Adoptive-cell therapy for the treatment of patients with cancer,” Nature Reviews Cancer, vol. 3, no. 9, pp. 666–675, 2003.

[7] M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients,” Journal of Immunotherapy, vol. 26, no. 4, pp. 332–342, 2003.

[8] L. Chang, W. C. Chang, G. McNamara, B. Aguilar, J. R. Ostberg, and M. C. Jensen, “Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning,” Cytotherapy, vol. 9, no. 8, pp. 771–784, 2007.

[9] Y. Zhao, Q. J. Wang, S. Yang et al., “A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity,” Journal of Immunology, vol. 183, no. 9, pp. 5563–5574, 2009.

[10] C. H. June, R. S. O’Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T cell immunotherapy for human cancer,” Science, vol. 359, no. 6382, pp. 1361–1365, 2018.

[11] S. Guedan, A. D. Posey Jr., E. Migliori, K. Willard-Gallo, and C. Solinas, “Targeting CTLA-4 in cancer: is it the ideal companion for PD-1 blockade immunotherapy combinations?,” International Journal of Cancer, 2020.

[12] X. Zhou, S. Tu, C. Wang et al., “Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas,” Frontiers in Immunology, vol. 11, article 539654, 2020.

[13] S. Bouziana and D. Bouzianas, “Anti-CD19 CAR-T cells: digging in the dark side of the golden therapy,” Critical Reviews in Oncology/Hematology, vol. 157, article 103096, 2020.

[14] Y. Zhao, Z. Liu, X. Wang et al., “Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies,” Clinical Cancer Research, vol. 25, no. 18, pp. 5595–5607, 2019.

[15] R. J. Brentjens, I. Riviere, J. H. Park et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood, vol. 118, no. 18, pp. 4817–4828, 2011.

[16] S. Gill and C. H. June, “Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies,” Immunological Reviews, vol. 263, no. 1, pp. 68–89, 2015.

[17] M. Canakci, K. Singh, O. Munkhbat et al., “Targeting CD4(+)-cells with anti-CD4 conjugated mertansine-loaded nanogels,” Biomacromolecules, vol. 21, no. 6, pp. 2473–2481, 2020.

[18] D. M. Weiner, J. S. Durgin, M. Wysocka, and A. H. Rook, “The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches,” Journal of the American Academy of Dermatology, vol. 84, no. 3, pp. 597–604, 2021.

[19] A. B. Gottlieb, M. Lebwohl, S. Shirin et al., “Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study,” Journal of the American Academy of Dermatology, vol. 43, no. 4, pp. 595–604, 2000.

[20] J. W. Lindsey, S. Hodgkinson, R. Mehta et al., “Phase Ⅰclinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis,” Neurology, vol. 44, 3, Part 1, pp. 413–419, 1994.

[21] B. W. van Oosten, M. Lai, S. Hodgkinson et al., “Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial,” Neurology, vol. 49, no. 2, pp. 351–357, 1997.

[22] B. H. Nilson, A. Solomon, L. Bjorck, and B. Akerstrom, “Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain,” The Journal of Biological Chemistry, vol. 267, no. 4, pp. 2234–2239, 1992.

[23] D. Miyashiro and J. A. Sanches, “Cutaneous manifestations of adult T-cell leukemia/lymphoma,” Seminars in Diagnostic Pathology, vol. 37, no. 2, pp. 81–91, 2020.

[24] A. E. Eladl, K. Soliman, Y. Suzuki et al., “EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma,” Cancer Medicine, vol. 9, no. 2, pp. 678–688, 2020.

[25] M. Jonker, W. Slingerland, G. Treacy et al., “In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees,” Clinical and Experimental Immunology, vol. 93, no. 3, pp. 301–307, 1993.